Highlights from the 2020 CHDI HD Therapeutics Conference are now here!
This year’s Postcard covers HTT-lowering therapeutics, including an update on the Roche ASO Phase 3 trial, brand new therapeutic approaches that have come out of the GWAS modifier gene studies, and a just-published study of premanifest HD in young adults.
